Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer

Human Pathology

Volumn 39, Issue 2, 2008, Pages 201-208

  Noike, Terumasa ^a   Miwa, Shiro ^a   Soeda, Junpei ^a   Kobayashi, Akira ^a   Miyagawa, Shin ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Liver metastasis; Redox factor 1; Thioredoxin; Vascular endothelial growth factor

Indexed keywords

REDOX EFFECTOR FACTOR 1; THIOREDOXIN 1; VASCULOTROPIN;

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL RATE; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38149090141     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.04.024     Document Type: Article

References (42)

1. Ballantyne G.H., and Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71 (1993) 4252-4266
2. Malafosse R., Penna C., Sa Cunha A., and Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 12 (2001) 887-894
3. Jamison R.L., Donohue J.H., Nagorney D.M., Rosen C.B., Harmsen W.S., and Ilstrup D.M. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 132 (1997) 505-511
4. Minagawa M., Makuuchi M., Torzilli G., et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231 (2000) 487-499
5. Imamura H., and Kawasaki S. Treatment strategy for multiple hepatic metastases of colorectal carcinoma. J Hepatobiliary Pancreat Surg 6 (1999) 23-29
6. Geoghegan J.G., and Scheele J. Treatment of colorectal liver metastases. Br J Surg 86 (1999) 158-169
7. Ercolani G., Grazi G.L., Ravaioli M., et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch Surg 137 (2002) 1187-1192
8. Hecht J.R. Metastasis in colorectal cancer: what makes the tumor aggressive?. Eur J Surg Suppl 582 (1998) 104-110
9. Ikeguchi M., Makino M., and Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol 77 (2001) 201-207
10. Tokunaga T., Oshika Y., Abe Y., et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77 (1998) 998-1002
11. Kawahara N., Tanaka T., Yokomizo A., et al. Enhanced coexpression of thioredoxin and high mobility group 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 56 (1996) 5330-5333
12. Sasada T., Iwata S., Sato N., et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97 (1996) 2268-2276
13. Holmgren A. Thioredoxin. Annu Rev Biochem 54 (1985) 237-271
14. Nakamura H., Nakamura K., and Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15 (1997) 351-369
15. Spyrou G., Enmark E., Miranda-Vizuete A., and Gustafsson A. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 272 (1997) 2936-2941
16. Powis G., and Montfort W.R. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41 (2001) 261-295
17. Powis G., Mustacich D., and Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29 (2000) 312-322
18. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16 (1996) 3459-3466
19. Gallegos A., Raffel J., Bhattacharyya A.K., and Powis G. Increased expression of thioredoxin in human primary and metastatic colon cancer. Proc Am Assoc Cancer Res 41 (2000) 189
20. Raffel J., Bhattacharyya A.K., Gallegos A., et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142 (2003) 46-51
21. Grogan T.M., Fenoglio-Prieser C., Zeheb R., et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31 (2000) 475-481
22. Nakamura H., Masutani H., Tagaya Y., et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69 (1992) 2091-2097
23. Rubartelli A., Bonifaci N., and Sitia R. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res 55 (1995) 675-680
24. Nakamura H., Bai J., Nishinaka Y., et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24 (2000) 53-60
25. Soini Y., Kahlos K., Näpänkangas U., et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7 (2001) 1750-1757
26. Kakokyris S., Giatromanolaki A., Koukourakis M., et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7 (2001) 3087-3091
27. Matsutani Y., Yamauchi A., Takahashi R., et al. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissue. Clin Cancer Res 7 (2001) 3430-3436
28. Fujii S., Nanbu Y., Nonogaki H., et al. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 68 (1991) 1583-1591
29. Wakita H., Yodoi J., Masutani H., Toda K., and Takigawa M. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions. J Invest Dermatol 99 (1992) 101-107
30. Toyokuni S., Okamoto K., Yodoi J., and Hiai H. Persistent oxidative stress in cancer. FEBS Lett 358 (1995) 1-3
31. Mitsui A., Hamuro J., Nakamura H., et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 4 (2002) 693-696
32. Nakamura H., Matsuda M., Furuke K., et al. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 42 (1994) 75-80
33. Welsh S.J., Bellamy W.T., Briehl M.M., and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62 (2002) 5089-5095
34. Hirota K., Murata M., Sachi Y., et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κB. J Biol Chem 274 (1999) 27891-27897
35. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94 (1997) 3633-3638
36. Ueno M., Masutani H., Arai R.J., et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274 (1999) 35809-35815
37. Evans A.R., Limp-Foster M., and Kelly M.R. Going APE over Ref-1. Mutat Res 461 (2000) 83-108
38. Tagaya Y., Maeda Y., Mitsui A., et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8 (1989) 757-764
39. Baker A., Payne C.M., Briehl M.M., and Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57 (1997) 5162-5167
40. Saitoh M., Nishitoh H., Fujii M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17 (1998) 2596-2606
41. Tanner B., Grimme S., Schiffer I., et al. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas. Gynecol Oncol 92 (2004) 568-577
42. Nishiyama A., Matsui M., Iwata S., et al. Identification of thioredoxin-binding protein-2/vitamin D (3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274 (1999) 21645-21650